Showing 85 to 96 of 123 results


GLP-1 Receptor Agonists: Significant Health Benefits and Risks Revealed in Large-Scale Study
A study of 1.4 million US veterans with type 2 diabetes revealed that GLP-1 receptor agonists, weekly-injected drugs, reduced the risk of 42 health issues, including cardiovascular problems and infections, but increased risks of gastrointestinal issues and low blood pressure.
GLP-1 Receptor Agonists: Significant Health Benefits and Risks Revealed in Large-Scale Study
A study of 1.4 million US veterans with type 2 diabetes revealed that GLP-1 receptor agonists, weekly-injected drugs, reduced the risk of 42 health issues, including cardiovascular problems and infections, but increased risks of gastrointestinal issues and low blood pressure.
Progress
40% Bias Score


GLP-1 Receptor Agonists: Significant Health Benefits and Risks Revealed in Large-Scale Study
A study of 1.4 million US veterans with type 2 diabetes showed that GLP-1 receptor agonists, weekly-injected drugs, reduced the risk of 42 health issues but increased the risk of 19 others, highlighting both benefits and risks of this increasingly popular medication.
GLP-1 Receptor Agonists: Significant Health Benefits and Risks Revealed in Large-Scale Study
A study of 1.4 million US veterans with type 2 diabetes showed that GLP-1 receptor agonists, weekly-injected drugs, reduced the risk of 42 health issues but increased the risk of 19 others, highlighting both benefits and risks of this increasingly popular medication.
Progress
36% Bias Score


Weight-Loss Drugs Double Pancreatitis Risk: Major Study
A Washington University study of over 2 million diabetes patients found that weight-loss drugs like Ozempic doubled the risk of pancreatitis and increased risks of nausea/vomiting (30%), arthritis (11%), headaches (10%), and sleep disturbances (12%), despite also showing benefits in cardiovascular a...
Weight-Loss Drugs Double Pancreatitis Risk: Major Study
A Washington University study of over 2 million diabetes patients found that weight-loss drugs like Ozempic doubled the risk of pancreatitis and increased risks of nausea/vomiting (30%), arthritis (11%), headaches (10%), and sleep disturbances (12%), despite also showing benefits in cardiovascular a...
Progress
52% Bias Score


Hypertension and Diabetes: Prevalence, Diagnosis, and Crucial Prevention
Hypertension affects nearly half of US adults, and diabetes impacts over 10%, significantly increasing cardiovascular risks; early diagnosis is vital due to the often asymptomatic nature of these conditions, necessitating preventative measures and treatment to reduce severe health consequences.
Hypertension and Diabetes: Prevalence, Diagnosis, and Crucial Prevention
Hypertension affects nearly half of US adults, and diabetes impacts over 10%, significantly increasing cardiovascular risks; early diagnosis is vital due to the often asymptomatic nature of these conditions, necessitating preventative measures and treatment to reduce severe health consequences.
Progress
16% Bias Score


Eli Lilly Stock Tumbles Despite Positive 2025 Outlook
Eli Lilly's stock fell over 7% on Tuesday after the company lowered its 2024 revenue outlook due to disappointing fourth-quarter sales of its GLP-1 weight-loss and diabetes drugs, Mounjaro and Zepbound, which missed estimates by a combined $500 million, despite resolving supply chain issues and main...
Eli Lilly Stock Tumbles Despite Positive 2025 Outlook
Eli Lilly's stock fell over 7% on Tuesday after the company lowered its 2024 revenue outlook due to disappointing fourth-quarter sales of its GLP-1 weight-loss and diabetes drugs, Mounjaro and Zepbound, which missed estimates by a combined $500 million, despite resolving supply chain issues and main...
Progress
40% Bias Score


BBVA Award Recognizes GLP-1 Hormone Discoverers for Diabetes, Obesity Treatments
The BBVA Foundation Frontiers of Knowledge Award in Biomedicine was given to four researchers for their discovery of the GLP-1 hormone's role in glucose regulation, appetite, and its implications for treating type 2 diabetes, obesity, and neurodegenerative diseases.
BBVA Award Recognizes GLP-1 Hormone Discoverers for Diabetes, Obesity Treatments
The BBVA Foundation Frontiers of Knowledge Award in Biomedicine was given to four researchers for their discovery of the GLP-1 hormone's role in glucose regulation, appetite, and its implications for treating type 2 diabetes, obesity, and neurodegenerative diseases.
Progress
32% Bias Score

High Blood Pressure and Diabetes Prevalence and Prevention in the US
Approximately half of US adults have high blood pressure, and over 10% have diabetes, significantly increasing heart disease and stroke risks; early diagnosis and treatment, even without symptoms, are crucial, with lifestyle changes and medications offering effective management.

High Blood Pressure and Diabetes Prevalence and Prevention in the US
Approximately half of US adults have high blood pressure, and over 10% have diabetes, significantly increasing heart disease and stroke risks; early diagnosis and treatment, even without symptoms, are crucial, with lifestyle changes and medications offering effective management.
Progress
16% Bias Score

GLP-1 Drugs Show Unexpected Health Impacts in Large-Scale Study
A study of 215,970 diabetic patients using GLP-1 receptor antagonist drugs found lower risks of 42 conditions (including cardiovascular disease, bacterial infections, and Alzheimer's) and higher risks of 19 (including nausea, low blood pressure, and joint pain) compared to other treatments; further ...

GLP-1 Drugs Show Unexpected Health Impacts in Large-Scale Study
A study of 215,970 diabetic patients using GLP-1 receptor antagonist drugs found lower risks of 42 conditions (including cardiovascular disease, bacterial infections, and Alzheimer's) and higher risks of 19 (including nausea, low blood pressure, and joint pain) compared to other treatments; further ...
Progress
16% Bias Score

GLP-1RA Medications: Reduced Risk of 42 Conditions, Increased Risk of 19 in Diabetic Patients
A study of 215,970 diabetic patients found GLP-1RA medications reduced the risk of 42 conditions (including psychotic disorders and dementia) by 13-19%, but increased the risk of 19 others (such as arthritis), based on a 3.5-year analysis of US Department of Veterans Affairs data.

GLP-1RA Medications: Reduced Risk of 42 Conditions, Increased Risk of 19 in Diabetic Patients
A study of 215,970 diabetic patients found GLP-1RA medications reduced the risk of 42 conditions (including psychotic disorders and dementia) by 13-19%, but increased the risk of 19 others (such as arthritis), based on a 3.5-year analysis of US Department of Veterans Affairs data.
Progress
40% Bias Score

Late Eating Linked to Higher Blood Glucose Levels, Regardless of Diet or Weight
A new study reveals that eating more than 45% of daily calories after 5:00 p.m. is associated with higher blood glucose levels, regardless of weight or diet, highlighting the importance of chrononutrition and suggesting potential implications for personalized dietary recommendations.

Late Eating Linked to Higher Blood Glucose Levels, Regardless of Diet or Weight
A new study reveals that eating more than 45% of daily calories after 5:00 p.m. is associated with higher blood glucose levels, regardless of weight or diet, highlighting the importance of chrononutrition and suggesting potential implications for personalized dietary recommendations.
Progress
36% Bias Score

Sugary Drinks Linked to Millions of Diabetes and Heart Disease Cases Annually
A new study finds that sugary drinks cause approximately 2.2 million new type 2 diabetes cases and 1.2 million new cardiovascular disease cases yearly globally, with the highest rates in Colombia (48% of new diabetes cases) and Mexico (nearly 33%).

Sugary Drinks Linked to Millions of Diabetes and Heart Disease Cases Annually
A new study finds that sugary drinks cause approximately 2.2 million new type 2 diabetes cases and 1.2 million new cardiovascular disease cases yearly globally, with the highest rates in Colombia (48% of new diabetes cases) and Mexico (nearly 33%).
Progress
40% Bias Score

Sugary Drinks Linked to Millions of Diabetes and Heart Disease Cases Globally
A study analyzed data from 184 countries (1990-2020) linking 2.2 million new Type 2 diabetes cases and 1.2 million new cardiovascular disease cases to sugary drinks in 2020; the highest impact was seen in sub-Saharan Africa, Latin America, the Caribbean, Colombia, Mexico, and South Africa; researche...

Sugary Drinks Linked to Millions of Diabetes and Heart Disease Cases Globally
A study analyzed data from 184 countries (1990-2020) linking 2.2 million new Type 2 diabetes cases and 1.2 million new cardiovascular disease cases to sugary drinks in 2020; the highest impact was seen in sub-Saharan Africa, Latin America, the Caribbean, Colombia, Mexico, and South Africa; researche...
Progress
44% Bias Score
Showing 85 to 96 of 123 results